ライフサイエンスコーパス: apheresis

1 ing apheresis at enrollment, 16 discontinued apheresis.

2 r placebo and 15 days later undergo platelet apheresis.

3 a mean of 4 +/- 3 days (range, 2-8 days) of apheresis.

4 CD34+ count of > or = 6/microL and underwent apheresis.

5 in the greatest quantity on the first day of apheresis.

6 iltration plasmapheresis and lipoprotein (a)-apheresis.

7 d predictably mobilizes HPCs and facilitates apheresis.

8 ilial hypercholesterolaemia, with or without apheresis.

9 e, and 243 (39%) of 621 received lipoprotein apheresis.

10 and mipomersen, and may reduce the need for apheresis.

11 lation with absolute lymphocyte count before apheresis.

12 ficantly lower CD3(+) cells and platelets at apheresis.

13 ific biomarkers before and after therapeutic apheresis.

14 hree (4%) among patients who did not receive apheresis.

15 removal of circulating factors with CytoSorb apheresis.

16 ry 2 weeks after 12 weeks in patients not on apheresis.

17 wering therapies with or without lipoprotein apheresis.

18 33% of normal allogeneic sibling donors in 1 apheresis.

19 tients received CAR T cells within 8 days of apheresis.

20 ary endpoint was to achieve this goal in one apheresis.

21 of whom 80 had received bendamustine before apheresis.

22 The symptoms began during stem cell apheresis.

23 onal therapy is with statins, ezetimibe, and apheresis.

24 ers based on T cell phenotype at the time of apheresis.

25 years; 8 patients were on ezetimibe and 7 on apheresis.

26 d-lowering treatment except ezetimibe and/or apheresis.

27 tin 20 mg alone or added to ezetimibe and/or apheresis.

28 oved by extracorporeal filtration during LDL apheresis.

29 which is markedly reduced after lipoprotein apheresis.

30 PET imaging 3 days (range 1 to 4 days) after apheresis.

31 th other lipid-lowering therapies, including apheresis.

32 colony-stimulating factor and collected via apheresis.

33 k of complications from CVC placement before apheresis.

34 eripheral blood stem cells" obtained through apheresis.

35 ly or 420 mg every 2 weeks if on lipoprotein apheresis.

36 ied European guidelines governing the use of apheresis.

37 ] vs 235 of 258 men [91.1%]) and lipoprotein apheresis (115 of 317 women [36.3%] vs 118 of 304 men [3

38 were significantly reduced after lipoprotein apheresis (284 +/- 118 mg/dl vs. 127 +/- 50 mg/dl; p < 0

39 Despite the proven benefits of LDL apheresis, access to this procedure remains limited beca

40 progenitor cells per unit of blood volume of apheresis after A + G administration versus G alone.

41 od (PB) mononuclear cells were collected via apheresis after high-dose cyclophosphamide and granulocy

42 ntinuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) aph

43 Therapeutic apheresis aims to selectively remove pathogenic substanc

44 ime of data lock, 204 patients had undergone apheresis and 189 were infused.

45 ization, intravenous catheter insertion, and apheresis and a median of 9 platelet transfusions was re

46 The time between apheresis and CAR T cell infusion is often not a simple

47 cyte colony-stimulating factor, underwent an apheresis and electromechanical mapping, and were random

48 Leukoreduction by apheresis and filtration resulted in substantial reducti

49 can be used as a predictor for the timing of apheresis and for estimating PBPC yield.

50 lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 1

51 Twenty-eight patients underwent apheresis and received CAR T cells.

52 s standard medical therapy (SMT) with no LDL apheresis and statin therapy alone.

53 owering therapy (ILLT) comprising single LDL apheresis and statins versus standard medical therapy (S

54 ovascular events, one (3%) among patients on apheresis and three (4%) among patients who did not rece

55 fine the patient population eligible for LDL apheresis and to create unified European guidelines gove

56 bers of mononuclear cells collected per 10-L apheresis and to increased concentrations of progenitors

57 , erythroid burst-forming units (1.8-fold/kg/apheresis), and colony-forming units-granulocyte-macroph

58 dministration of intravenous immunoglobulin, apheresis, and combination therapies using potent immuno

59 yte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas

60 were mobilized by filgrastim, collected via apheresis, and labeled with technetium-99m radioisotope

61 lar regardless of age or use of ezetimibe or apheresis, and was maintained for 12 weeks.

62 Similar changes were observed for the apheresis- and sham-treatment groups for endoscopic remi

63 ing apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration,

64 cytokines, and ongoing trials with leukocyte apheresis are currently under way.

65 telets (SDP) obtained from a single donor by apheresis are indicated to treat acute hemorrhage second

66 Intravenous gamma globulin and selective apheresis are niche therapies appropriate in a few, high

67 ts identified naive T cells in pre-treatment apheresis associated with good expansion, and exhausted

68 entified CXCR3(+) monocytes in pre-treatment apheresis associated with good expansion.

69 Of 61 patients receiving apheresis at enrollment, 16 discontinued apheresis.

70 were included in this analysis, 34 receiving apheresis at study entry and 14 younger than 18 years.

71 47 of 72 patients not on apheresis at study entry increased evolocumab dosing to

72 s with FH and, moreover, whether lipoprotein apheresis attenuates arterial wall inflammation in FH pa

73 Apheresis began on day 4 of G-CSF administration.

74 SCF and 10 microg/kg/d filgrastim with daily apheresis beginning on day 5 was selected as the optimal

75 d is achieved in most patients with a single apheresis, but an optimal collection usually requires at

76 delines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking

77 supports the hypothesis that extracorporeal apheresis can lower circulating sFlt-1 in very preterm p

78 An 8-F 24-cm-long apheresis catheter was placed in the basilic vein with i

79 marrow collection by sequential COBE Spectra apheresis (COBE BCT, Lakewood, CO), CD34+ enrichment usi

80 tential of utilizing cryopreserved mobilized apheresis collected earlier in the disease course to pro

81 the shelf life and preserved the function of apheresis-collected human GTX products both ex vivo and

82 /=2 x 10(6) CD34(+)/kg recipient weight in 1 apheresis collection to </=10% was not reached.

83 timal proportion of the platelet supply from apheresis collections and the choice of whole-blood-deri

84 At least three daily 12-L apheresis collections were performed on each donor.

85 yopreserved peripheral blood leukocytes from apheresis collections.

86 dration, and reducing blood flow through the apheresis column.

87 fusion increments for platelets derived from apheresis compared with platelet-rich plasma whole-blood

88 ng units-granulocyte-macrophage (2.2-fold/kg/apheresis) compared with regimen G given to the same pat

89 After 12 weeks, those not on apheresis could be up-titrated to 420 mg every 2 weeks.

90 pheral blood samples ranging from the day of apheresis (day -28/baseline) to 28 days after CAR-T infu

91 34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.

92 or = 5 x 10(6) CD34+ cells/kg in 4 or fewer apheresis days.

93 ature-based review of the relative merits of apheresis-derived and whole-blood-derived platelets.

94 , and may eventually combine the benefits of apheresis-derived and whole-blood-derived platelets.

95 whole blood-derived platelet-rich plasma to apheresis-derived platelet concentrates.

96 Apheresis-derived, autologous, lymphocyte-rich cells rad

97 Unfortunately, current apheresis devices cannot handle small blood volumes in i

98 , the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes.

99 However, criteria for LDL apheresis eligibility and the percentage of patients rec

100 Platelet transfusions total >2.17 million apheresis-equivalent units per year in the United States

101 a 70% reduction in fibrinogen, and following apheresis, erythrocyte rouleaux formation and fibrin fib

102 ilization of more CD34(+) cells (2.7-fold/kg/apheresis), erythroid burst-forming units (1.8-fold/kg/a

103 umab 420 mg subcutaneously monthly, or if on apheresis every 2 weeks.

104 ckground lipid-lowering treatment and not on apheresis, evolocumab 420 mg administered every 4 weeks

105 lds were substantially higher with the first apheresis following rhTPO and G-CSF versus G-CSF alone:

106 efficacy and low incidence of side-effects, apheresis for severe drug-refractory hypercholesterolemi

107 ibe and PCSK9 inhibitors; use of lipoprotein apheresis for severe FH; and addressing barriers to care

108 Starting on day 5, patients began daily apheresis for up to 4 days or until > or = 5 x 10(6) CD3

109 Starting on day 5, patients began daily apheresis for up to 4 days or until more than or equal t

110 asma (PPP) samples were obtained by platelet-apheresis from severe (n = 7) and mild (n = 10) allergic

111 Human platelets collected by apheresis had low levels of platelet activation markers.

112 PSCT patients who received a tumor-negative apheresis harvest was 64%, compared with 57% for patient

113 Therapeutic apheresis has been suggested as an efficient treatment o

114 Selective Lp(a) apheresis has offered some evidence that Lp(a)-lowering

115 Several days later, after apheresis, he received his first of two cycles of high-d

116 wed by the collection of mobilized cells via apheresis in 3 deceased donors.

117 GM-CFC threshold was achieved with a single apheresis in 83% of patients and in 90% with two apheres

118 System (JIMRO, Ltd, Takasaki, Japan) or sham apheresis in a 2:1 ratio for 9 weeks of treatment in a N

119 aluated the efficacy of granulocyte/monocyte apheresis in a randomized, double-blind, sham-controlled

120 uence of pretreatment corticosteroids and/or apheresis in altering the efficacy of treatment.

121 bear on the evidential basis for therapeutic apheresis in diseases in which hemolytic anemia is a pro

122 easured frequently before, during, and after apheresis in four HIV-1-infected patients, two of whom w

123 counts and consequently platelet yields from apheresis in healthy platelet donors.

124 setting them up, the efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia a

125 We carried out plasma apheresis in mouse models, each with a blood volume of j

126 or early coronary plaque regression with LDL apheresis in nonfamilial hyperlipidemia acute coronary s

127 ive Lipid Elimination Regimen) evaluated LDL apheresis in nonfamilial hyperlipidemia acute coronary s

128 Following a double-membrane extracorporeal apheresis in patients with AD, there was a significant r

129 019, 78 patients were enrolled and underwent apheresis in phase 2 of the study.

130 ong-term benefits of low-density lipoprotein apheresis in severely hypercholesterolemic patients who

131 , we posit a potential use of extracorporeal apheresis in the prevention and treatment of AD.

132 Lipoprotein apheresis is an option for very high Lp(a) with progress

133 Lipoprotein apheresis is being performed with increasing frequency,

134 LDL apheresis is currently the best treatment option (or tre

135 Lipoprotein apheresis is indicated for coronary artery disease (CAD)

136 ope have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative c

137 Apheresis is still the treatment of choice in homozygous

138 RECENT FINDINGS: Apheresis is the most efficacious method to lower Lp(a).

139 to assess the effect of chronic lipoprotein apheresis (LA) on the incidence of cardiovascular events

140 h pharmacologic intervention and lipoprotein apheresis (LA)-is foundational.

141 Dextran sulfate apheresis lowered circulating sFlt-1, reduced proteinuri

142 had more naive and less exhausted T cells in apheresis material and improved functional T cell phenot

143 ese differences could be tracked back to the apheresis materials prior to CAR T cell manufacturing.

144 in combination with low-density lipoprotein apheresis may confer significant benefits toward prevent

145 ere 17% and 11% for the granulocyte/monocyte apheresis (n = 112)- and sham-treatment groups, respecti

146 emotherapy regimens, and more than 5 days of apheresis needed to harvest enough stem cells were ident

147 ntisense oligonucleotides and by lipoprotein apheresis, niacin therapy and bariatric surgery.

148 tudinally from (1) mobilized, unfractionated apheresis obtained before hematopoietic cell transplanta

149 oietic cell transplantation (mobHCT) and (2) apheresis obtained for commercial CAR-T manufacture (aph

150 ficking into the liver was not observed, and apheresis of mobilized cells resulted in a uniform decre

151 Apheresis of multiple donors allowed isolation of autolo

152 This process entails apheresis of the patient's T cells, followed by CAR T ce

153 gous FH, therapy during pregnancy and use of apheresis) of patients with FH, update evidence-informed

154 aneous daily for 5 days was followed by 12-L apheresis on the fifth day.

155 ibe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis

156 IdeS treatment, by therapeutic apheresis or direct administration, may be beneficial in

157 ody titres are deemed amenable to removal by apheresis or immunoabsorption.

158 nts such as cell and tissue transplantation, apheresis or parabiosis.Clarifying the source of protein

159 Single-donor apheresis or pooled whole blood-derived platelets in add

160 Each group also received 1 U platelets (apheresis or prepooled random donor) for every 6 U of mW

161 , CLABSI (OR, 6.39; 95% CI, 3.02-13.52), and apheresis (OR, 1.77; 95% CI, 1.22-2.55) had higher odds

162 the profound cholesterol-lowering effects of apheresis, other potentially beneficial phenomena have b

163 from reductions achieved in patients not on apheresis (p=0.38 at week 12 and p=0.09 at week 48).

164 CD34(+) cells (median, 7.1 v 2.0 x 10(6)/kg/apheresis; P =.0001), and a higher fraction achieved 2.5

165 her levels of sCD40L than fresh plasma, with apheresis PCs evidencing the highest concentration of sC

166 y-stimulating factor (G-CSF), with the first apheresis performed when the recovery WBC count was > or

167 Pre- and post-apheresis plasma from 6 patients with familial hyperchol

168 Fractionation of pre- and post-apheresis plasma showed that 81 +/- 11% of LDL-bound PCS

169 More than 1 million apheresis platelet collections are performed annually in

170 emia were randomized to receive prophylactic apheresis platelet concentrates when the platelet count

171 We studied ABH expression in 166 group A apheresis platelet donors by flow cytometry, Western blo

172 filtered red blood cell (RBC) units (but not apheresis platelet products) from CMV-positive donors as

173 A single Trima apheresis platelet unit (n = 12) was aliquoted into five

174 n with whole blood platelets (72 reactions), apheresis platelets (2), packed red cells (15), and plas

175 At 2 locations over 3 allergy seasons, apheresis platelets and whole blood were collected from

176 althy donors to provide a median 3-fold more apheresis platelets compared with untreated donors.

177 onducted transfusing radiolabeled autologous apheresis platelets stored for 48 hours at 4 degrees C w

178 To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% plat

179 alents [GE]/mL) resulting in 32 evaluable LR apheresis platelets, 31 filtered platelets from whole bl

180 ts were generally higher for transfusions of apheresis platelets, ABO-identical platelets, and platel

181 a volume components, fresh frozen plasma and apheresis platelets, from potentially alloimmunized dono

182 ts of fresh frozen plasma and 6,251 units of apheresis platelets, we identified 112 patients who rece

183 ion process by adding UDP-galactose to human apheresis platelets.

184 ience of or an equivalent level of safety as apheresis platelets.

185 platelets transfused or transfusing filtered apheresis platelets.

186 pheral procurement of the stem cells through apheresis possible.

187 o simultaneously profile all RNA biotypes in apheresis-prepared human plasma pooled from healthy indi

188 (+) cells/kg was procured following a single apheresis procedure in 61% of the rhTPO and G-CSF-mobili

189 criteria for lipoprotein apheresis underwent apheresis procedures followed by a second FDG-PET imagin

190 d group of patients, decreases the number of apheresis procedures required, may accelerate hematopoie

191 h A + G compared with G alone required fewer apheresis procedures to reach the target level at least

192 ntly greater CD34(+) HSPC numbers within two apheresis procedures versus placebo + G-CSF while prefer

193 s than 3 x 10(6)/kg and need for more than 2 apheresis procedures.

194 Subsequently, they underwent four to five apheresis procedures.

195 >=6 x 10(6) CD34(+) cells kg(-1) within two apheresis procedures; the secondary endpoint was to achi

196 associated with G-CSF administration and the apheresis process included myalgias/arthralgias (83%), h

197 d that filgrastim mobilization, large volume apheresis, processing, and cryopreservation appears to b

198 ich was already detectable in the CAR T-cell apheresis product and the final CAR T-cell product at ve

199 However, tumor cells contaminating the apheresis product are a potential source of relapse.

200 CAR-T through both modulation of the T-cell apheresis product composition and promoting a more favor

201 eneficial synergistic effect of ibrutinib on apheresis product fitness, CAR-T expansion, and toxicity

202 ngement, which was already detectable in the apheresis product for CAR T-cell manufacturing and 7 mon

203 One apheresis product from each patient was prepared using t

204 eliminate the cancer cells in the patient's apheresis product from the healthy immune cells.

205 CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feas

206 CAR T cell infusion products, along with the apheresis product used as the starting material for CAR

207 units-erythroid (BFU-E) per kilogram in the apheresis product was similar when all patients were ana

208 n can interfere with biological functions of apheresis products and adoptively transferred T cells.

209 sively removing cancerous cells from patient apheresis products for safe manufacturing of adoptive T-

210 CTLs are generated from apheresis products from individuals who have recovered f

211 presumed fetal microchimerism) is present in apheresis products of female donors.

212 Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and cocul

213 In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in

214 either pretreatment with corticosteroids nor apheresis reduced the efficacy of the diethylcarbamazine

215 or ACS and up to 14 days following the final apheresis/reinfusion session.

216 HDL selective delipidated or control plasma apheresis/reinfusions.

217 ften (17% vs 4%, P< .001), experiencing more apheresis-related AEs (20% vs 7%, P< .001), more bone pa

218 a) levels has been only modestly successful; apheresis remains the most effective therapeutic modalit

219 nd the impracticality of regular lipoprotein apheresis represent major challenges to currently availa

220 Our analysis aids in defining apheresis resource utilization and helps in risk stratif

221 studies on nonamplified mRNA from pooled or apheresis samples, respectively.

222 Lipoprotein apheresis seems to be going through a growth spurt, pres

223 this treatment may (1) reduce the number of apheresis sessions and/or amount of G-CSF required to co

224 ir progeny were detected in the PTCL, in the apheresis specimen that was obtained for CAR T-cell prod

225 locyte/monocyte apheresis with the Adacolumn Apheresis System (JIMRO, Ltd, Takasaki, Japan) or sham a

226 through an acoustofluidic-based therapeutic apheresis system designed for processing small blood vol

227 Extracorporeal lipoprotein apheresis systems employ well-established, powerful meth

228 Current apheresis systems require large blood volumes and are pr

229 s (PE) is an established form of therapeutic apheresis (TA).

230 n of arterial inflammation after lipoprotein apheresis (TBR: 2.05 +/- 0.31 vs. 1.91 +/- 0.33; p < 0.0

231 Selective apheresis techniques (cytapheresis, immunoadsorption) of

232 heresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, protea

233 cells in the early 1960s, the development of apheresis technology, the discovery of hematopoietic gro

234 rovement following two cycles of therapeutic apheresis, there was a significant reduction in neurotra

235 on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 4

236 utilizing previously cryopreserved mobilized apheresis to generate potent anti-BCMA CAR-T cells.

237 n decisions regarding timing and duration of apheresis to harvest a specific number of these cells.

238 titis C virus (HCV) dynamics, we used plasma apheresis to increase virion clearance temporarily while

239 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram

240 Patients underwent apheresis to obtain at least 1 x 10(9) lymphocytes to ma

241 The use of LDL-apheresis to treat patients with severe hypercholesterol

242 rate that a single dextran sulfate cellulose apheresis treatment reduces circulating sFlt-1 levels in

243 Finally, we performed multiple apheresis treatments in 3 additional women with very pre

244 s after one (n=6), two (n=4), or three (n=1) apheresis treatments.

245 atients who met the criteria for lipoprotein apheresis underwent apheresis procedures followed by a s

246 lower doses equal to one half of a standard apheresis unit are equally effective.

247 e AABB recommends transfusing up to a single apheresis unit or equivalent.

248 tly, the non-evidence-based preponderance of apheresis units in the United States and the 50: 50 rati

249 Extracorporeal apheresis using a special filter seems to be effective i

250 be accomplished, for example, by therapeutic apheresis using surface-immobilized EndoS.

251 We compared apheresis utilization and transplant outcomes in ABOi, X

252 ics, such as platelet dose, platelet source (apheresis vs pooled), platelet donor-recipient ABO compa

253 The median cell content of the two apheresis was 11.9 x 10(8) WBC/kg, 3.2 x 10(8) CD3/kg, a

254 recipients who received immunoadsorption or apheresis was 94.1% (95% confidence interval [95%CI], 88

255 Recent bendamustine exposure before apheresis was associated with negative treatment outcome

256 ection (CLABSI), central venous catheter, or apheresis was associated with the diagnosis of bacteremi

257 Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antih

258 d, multicenter trial of Prosorba versus sham apheresis was performed in patients with RA who had fail

259 Apheresis was performed on 2 consecutive days.

260 In this study, granulocyte/monocyte apheresis was well tolerated but did not demonstrate eff

261 psia (n=22 per group), no adverse effects of apheresis were observed.

262 reductions in LDL cholesterol in patients on apheresis were significant at week 12 (p=0.0012) and wee

263 nt kidney and immediate response to CytoSorb apheresis were still suggestive for pathogenic circulati

264 least 4 weeks, and not receiving lipoprotein apheresis, were randomly allocated by a computer-generat

265 In addition to improving access to apheresis where appropriate, new therapies are needed to

266 or-treated patients reached target after one apheresis, whereas 56% of the placebo-treated patients r

267 safety and potential efficacy of therapeutic apheresis with a plasma-specific dextran sulfate column

268 associated an activated T-cell phenotype at apheresis with a response to MCARH109.

269 s intervention, we used granulocyte/monocyte apheresis with the Adacolumn Apheresis System (JIMRO, Lt

270 Apheresis with the Prosorba column is an efficacious tre

271 progenitor cells were observed early during apheresis, with 9 of 12 patients mobilizing adequate amo

272 d 12 weekly treatments with Prosorba or sham apheresis, with efficacy evaluated 7-8 weeks after treat

273 when leukocyte-reduced platelets obtained by apheresis without filtration were also used.